Targovax ASA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.10.18	Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City Today, 11 October, 2018 (PR Newswire)
11.10.18	Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City Today, 11 October, 2018 (PR Newswire)
04.10.18	Targovax to Host Capital Markets Day 15 October 2018, in Oslo, Norway (PR Newswire)
04.10.18	Targovax to Host Capital Markets Day 15 October 2018, in Oslo, Norway (PR Newswire)
01.10.18	Targovax Presented ONCOS-102 Poster at 13th International Adenovirus Meeting (PR Newswire)
01.10.18	Targovax Presented ONCOS-102 Poster at 13th International Adenovirus Meeting (PR Newswire)
27.09.18	Targovax Announces Interim Results From Phase I Trial of ONCOS-102 in Checkpoint Inhibitor Refractory Melanoma (PR Newswire)
27.09.18	Targovax Announces Interim Results From Phase I Trial of ONCOS-102 in Checkpoint Inhibitor Refractory Melanoma (PR Newswire)
27.09.18	Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018 (PR Newswire)
27.09.18	Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018 (PR Newswire)
13.09.18	Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO (PR Newswire)
13.09.18	Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO (PR Newswire)
12.09.18	Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy (PR Newswire)
12.09.18	Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy (PR Newswire)
23.08.18	Targovax ASA: Second Quarter and First Half Year 2018 Results (PR Newswire)
23.08.18	Targovax ASA: Second Quarter and First Half Year 2018 Results (PR Newswire)
15.08.18	Targovax ASA: Invitation to Second Quarter and First Half Year 2018 Results Presentation Thursday 23 August (PR Newswire)
15.08.18	Targovax ASA: Invitation to Second Quarter and First Half Year 2018 Results Presentation Thursday 23 August (PR Newswire)
12.07.18	Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC (PR Newswire)
12.07.18	Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC (PR Newswire)
19.06.18	Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02 (PR Newswire)
19.06.18	Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02 (PR Newswire)
12.06.18	Targovax Hosts Conference Call 12 June 2018 (PR Newswire)
12.06.18	Targovax Hosts Conference Call 12 June 2018 (PR Newswire)
11.06.18	Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program (PR Newswire)
11.06.18	Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program (PR Newswire)
04.06.18	Targovax to Present at Jefferies 2018 Global Healthcare Conference (PR Newswire)
04.06.18	Targovax to Present at Jefferies 2018 Global Healthcare Conference (PR Newswire)
24.05.18	Targovax Strengthens 2-year Survival Rate in Resected Pancreatic Cancer With TG01 (PR Newswire)
24.05.18	Targovax Strengthens 2-year Survival Rate in Resected Pancreatic Cancer With TG01 (PR Newswire)
03.05.18	Targovax ASA: First quarter 2018 results (GlobeNewswire)
02.05.18	Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma (GlobeNewswire)
25.04.18	Targovax presentation at ChinaBio Partnering Forum 2018 (GlobeNewswire)
24.04.18	Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May (GlobeNewswire)
12.04.18	Targovax strengthens Board of Directors with the appointment of Catherine Wheeler (GlobeNewswire)
11.04.18	Targovax ASA: Protocol from the Annual General Meeting (GlobeNewswire)
24.03.18	Targovax ASA: Proposal from the nomination committee to the annual general meeting 11 April 2018 (GlobeNewswire)
15.03.18	Targovax ASA: Notice of Annual General Meeting (GlobeNewswire)
15.03.18	Targovax ASA: Annual Report 2017 (GlobeNewswire)
27.02.18	Targovax to present at Biologics World Nordic 2018 (GlobeNewswire)
15.02.18	Targovax ASA: Fourth quarter and full year 2017 results (GlobeNewswire)
07.02.18	Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma (GlobeNewswire)
06.02.18	Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February (GlobeNewswire)
08.01.18	Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer (GlobeNewswire)
04.01.18	Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients (GlobeNewswire)
18.12.17	Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer (GlobeNewswire)
13.12.17	Targovax to present at DNB healthcare conference (GlobeNewswire)
11.12.17	Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews (GlobeNewswire)
30.11.17	Targovax ASA: New member of the board of directors (GlobeNewswire)
14.11.17	Targovax to present at upcoming investor conferences (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Targovax ASA

Aktien Top/Flop

Meistgelesene Nachrichten